---
title: "blinatumomab"
slug: "blinatumomab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[relapse refractory of treatment of acute lymphoblastic leukemia (ALL)]]

# blinatumomab

> bispecific T-cell-engaging (BiTE) antibody against CD19
> bli-na-TUMO-mab

- Mechanism:
  - Binds CD19 on malignant B-cells & CD3 on T-cells
- Dosing:
  - Cycle 1:9-mcg continuous infusion daily (d 1-7),
  - followed by 28-mcg continuous infusion daily (d 8-28); cycle 2-5: 28-mcg continuous infusion daily (1-28) every 6 wks;. Cycles for MRD: 28-mcg continuous infusion
- PK/PD: T1/2 âˆ¼2 h
- AEs: CRS, neurologic tox, fever, peripheral edema, diarrhea, â†‘ liver enzymes
- DDI: No known pathways of metabolism, avoid live, & inactivated vaccines
- Clinical pearls:
  - Admission required for initiation & for subsequent cycles for varying duration dependent on disease burden

- CD19 BiTE-bispecific T-cell engager;Â NEJM2017;376:836
- B å‹ç™½è¡€ç—…ï¼šç™¾åˆ©å¦¥(Blinatumomab, Blincyto)
- å¥ä¿çµ¦ä»˜ä½¿ç”¨åœ¨é ‘å›ºå‹æˆ–æ˜¯å¾©ç™¼å‹çš„ B ç´°èƒå‹æ€¥æ€§æ·‹å·´æ€§ç™½è¡€ç—…ã€‚

---

- é›™ç‰¹ç•°æ€§ T ç´°èƒæ¥åˆå™¨ï¼Œ
- å¼•å°é«”å…§ CD3 T cellï¼Œ
- ğŸš«å…·æœ‰ CD19 æ¨™è¨˜çš„ B ç´°èƒ (æ€¥æ€§æ·‹å·´æ€§ç™½è¡€ç—…çš„ç™Œç´°èƒ) ç‚ºç›®æ¨™

---

- é€²è¡Œé€£çµï¼Œæ´»åŒ–å…§ç”Ÿçš„ T ç´°èƒ
- æ´»åŒ–çš„ T ç´°èƒæœƒå½±éŸ¿ç™Œç´°èƒçš„çªè§¸ç”Ÿæˆ
- é€²è€Œå¢åŠ  â†‘ ç´°èƒé»é™„åˆ†å­
- ç”¢ç”Ÿ â†ª ç´°èƒæº¶è•è›‹ç™½èˆ‡é‡‹å‡ºç™¼ç‚æ€§ç´°èƒæ¿€ç´ 
- æœ€çµ‚ä½¿å…·æœ‰ CD19 æ¨™è¨˜çš„ç™Œç´°èƒå°å‘æ­»äº¡

### Backlink

- [[relapse refractory of treatment of acute lymphoblastic leukemia (ALL)]]
- [[acute lymphoblastic leukemia]]
- [[Monoclonal Antibodies]]
